Clinical trialNCT01294670CompletedPhase 1/PHASE2Interventional

Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

SponsorMemorial Sloan Kettering Cancer CenterEnrollment27Relapsed/Refractory SarcomasSolid Tumors

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out how safe and effective treatment with a new combination of drugs, vorinostat and etoposide, is in treating cancer. The medication etoposide is a standard medication used in the treatment of cancer in children. Vorinostat is an experimental drug which targets a protein(s) that control the way cancer cells grow and divide. Vorinostat is approved by the FDA in adults with certain cancers but not approved yet in children. There are two parts to this study. In the first part of this study, the phase I portion, a safe dose of the combination, vorinostat and etoposide. The goal of second part of this study, the phase II portion, is to see how effective the combination of vorinostat and etoposide is in treating cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Tanya Trippett, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

11 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Alberta Children'S Hospital
Calgary, Alberta, Canada

United States

Phoenix Children'S Hospital
Phoenix, Arizona, United States
Children'S Hospital Colorado
Aurora, Colorado, United States
Arnold Palmer Hospital for Children/md Anderson Cancer Center Orlando
Orlando, Florida, United States
All Children'S Hospital
St. Petersburg, Florida, United States
John Hopkins Medical Center
Baltimore, Maryland, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Children'S Mercy Hospital & Clinics
Kansas City, Missouri, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Pennsylvania State University College of Medicine
Hershey, Pennsylvania, United States
Md Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Vorinostat and Etoposide

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 9 Feb 2011
Primary completion: 8 Dec 2020
Completion: 8 Dec 2020
Last update posted: 18 Nov 2021
Registered enrollment: 27
Registry id: NCT01294670

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.